Substituted alkylphenols as HCN1 antagonists
AssigneeCornell University
InventorsGareth R. Tibbs, Peter A. Goldstein, Anthony A. Sauve, Rajendra Uprety, James David Warren, Jr., Rebecca L. Joyce, Dipti N. Barman
Life of this patent
Estimating the term…
Abstract
Provided herein are compounds (e.g., compounds of Formula (I) and Formula (II), that modulate HCN channels, intermembrane proteins that serve as nonselective voltage-gated cation channels in the plasma membranes of heart and brain cells. Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating HCN-related disorders (e.g., pain) with the compounds in a subject, by administering the compounds and/or compositions described herein.
Claims10
A method of treating pain in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of formula:
- or a pharmaceutically acceptable salt thereof.
A method of modulating HCN channel gating, the method comprising contacting an HCN channel with an effective amount of a compound of formula:
- or a pharmaceutically acceptable salt thereof.
A method of inhibiting an HCN1 channel without enhancing a gamma-aminobutyric acid-A (GABA-A) receptor, the method comprising contacting an HCN1 channel with an effective amount a compound of formula:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.